The Tomosynthesis Mammographic Imaging Screening Trial, known as TMIST or study EA1151, is comparing two types of digital mammography approved by the Food and Drug Administration: tomosynthesis (known as three-dimensional, or 3-D) and conventional (two-dimensional, or 2-D). Although 3-D mammography, being the newer technology, is likely to detect more findings that require follow-up, it is also likely to lead to more procedures and treatments. It is not known if the newer technology is more effective than conventional 2-D mammography at reducing life-threatening (advanced) breast cancers. The TMIST trial aims to find out.
The ECOG-ACRIN Cancer Research Group opened the trial on July 6, 2017, and plans to enroll about 165,000 women by the end of 2020.
In order to participate in the study, women must be
In addition, women must not
If a woman decides to participate, she will be involved in this research study for at least eight years starting with her next scheduled mammogram. During that time:
The trial will take place at about 100 vetted mammography clinics, mostly in the United States and a few clinics in Canada. To ensure that TMIST enrolls a diverse group of women, the trial clinics will be located in large and small communities throughout the United States, and the women they serve will reflect the country’s racially and ethnically diverse population. The selected mammography clinics will join the trial on a rolling basis between the fall of 2017 and spring of 2018. Before opening the trial, each clinic must receive IRB approval, submit evidence of rigorous pre-testing of imaging equipment, and complete staff training requirements specifically for this trial. Follow this link to view trial locations
Inquiries about TMIST may be directed to:
ECOG-ACRIN Cancer Research Group
Operations Office – Boston
TMIST is publicly funded by the National Cancer Institute, part of the National Institutes of Health, through the NCI Community Oncology Research Program.